In the BioHarmony Drug Report Database

"Preview" Icon

Nintedanib

Ofev, Vargatef (nintedanib) is a small molecule pharmaceutical. Nintedanib was first approved as Ofev on 2014-10-15. It is used to treat idiopathic pulmonary fibrosis in the USA. It has been approved in Europe to treat idiopathic pulmonary fibrosis and non-small-cell lung carcinoma. The pharmaceutical is active against vascular endothelial growth factor receptor 3. In addition, it is known to target platelet-derived growth factor receptor beta, vascular endothelial growth factor receptor 2, platelet-derived growth factor receptor alpha, fibroblast growth factor receptor 4, vascular endothelial growth factor receptor 1, fibroblast growth factor receptor 3, fibroblast growth factor receptor 1, and fibroblast growth factor receptor 2. Ofev’s patents are valid until 2029-06-07 (FDA).

 

Trade Name

 

Ofev, Vargatef
 

Common Name

 

nintedanib
 

ChEMBL ID

 

CHEMBL502835
 

Indication

 

idiopathic pulmonary fibrosis, non-small-cell lung carcinoma
 

Drug Class

 

Angiogenesis inhibitors

Image (chem structure or protein)

Nintedanib structure rendering